Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report

Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report

Abstract Background Homologous recombination deficiency is a marker of response to poly(ADP-ribose) polymerase inhibitors in different cancer types including ovary, prostate, and pancreatic cancer. To date, no report about poly(ADP-ribose) polymerase inhibitors has been published on cervical cancer....

Full description

Bibliographic Details
Main Authors: Rosa Montero-Macias, Meriem Koual, Céline Crespel, Marie Aude Le Frére-Belda, Hélène Blons Hélène, Huyen-Thu Nguyen-Xuan, Simon Garinet, Géraldine Perkins, Vincent Balay, Catherine Durdux, Marie Florin, Hélène Péré, Anne-Sophie Bats
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Journal of Medical Case Reports
Subjects:
Advanced cervical cancer
BRCA1
PARP inhibitor
Olaparib
Precision oncology
Online Access:https://doi.org/10.1186/s13256-021-02767-9

Internet

https://doi.org/10.1186/s13256-021-02767-9

Similar Items